Long-lived autoreactive plasma cells drive persistent autoimmune inflammation

Nature Reviews Rheumatology

Volumn 7, Issue 3, 2011, Pages 170-178

  Hiepe, Falk ^a   Dörner, Thomas ^a   Hauser, Anja E ^b   Hoyer, Bimba F ^a   Mei, Henrik ^a   Radbruch, Andreas ^b  

^a POTSDAM INSTITUTE FOR CLIMATE IMPACT RESEARCH PIK   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BORTEZOMIB; CYCLOPHOSPHAMIDE; NATALIZUMAB; THYMOCYTE ANTIBODY;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE SUBPOPULATION; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; CELL DIFFERENTIATION; HUMANS; INFLAMMATION; PLASMA CELLS;

EID: 79952452617     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.1     Document Type: Review

References (104)

1. Zinkernagel, R. M. et al. On immunological memory. Annu. Rev. Immunol. 14, 333-367 (1996). (Pubitemid 26130188)
2. Manz, R. A., Thiel, A. & Radbruch, A. Lifetime of plasma cells in the bone marrow. Nature 388, 133-134 (1997). (Pubitemid 27297440)
3. Manz, R. A., Löhning, M., Cassese, G., Thiel, A. & Radbruch, A. Survival of long-lived plasma cells is independent of antigen. Int Immunol. 10, 1703-1711 (1998). (Pubitemid 28502384)
4. Slifka, M. K., Antia, R., Whitmire, J. K. & Ahmed, R. Humoral immunity due to long-lived plasma cells. Immunity 8, 363-372 (1998). (Pubitemid 28188896)
5. Martin, F. & Chan, A. C B cell immunobiology in disease: evolving concepts from the clinic Annu. Rev. Immunol. 24, 467-496 (2006).
6. Gould, H. J. & Sutton, B. J. Ige in allergy and asthma today Nat Rev. Immunol. 8, 205-217 (2008). (Pubitemid 351323292)
7. Hoyer, B. F. et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/w mice. J. Exp. Med. 199, 1577-1584 (2004). (Pubitemid 38780412)
8. Luger, E. O. et al. Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge. J. Allergy Clin. Immunol. 124, 819-826 (2009).
9. Tarlinton, D., Radbruch, A., Hiepe, F. & Dörner, T. Plasma cell differentiation and survival. Curr. Opin. Immunol. 20, 162-169 (2008).
10. Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev. Immunol. 6, 741-750 (2006). (Pubitemid 44453460)
11. Hargreaves, D. C et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J. Exp. Med. 194, 45-56 (2001). (Pubitemid 32660436)
12. Hauser, A. E. et al. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J. Immunol. 169, 1277-1282 (2002). (Pubitemid 34809169)
13. Muehlinghaus, G. et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 105, 3965-3971 (2005). (Pubitemid 40656144)
14. Manz, R. A., Hauser, A. E., Hiepe, F. & Radbruch, A. Maintenance of serum antibody levels. Annu. Rev. Immunol. 23, 367-386 (2005). (Pubitemid 40563174)
15. MacLennan, I. C & Gray D. Antigen-driven selection of virgin and memory B cells. Immunol. Rev. 91, 61-85 (1986). (Pubitemid 16070599)
16. Cappione, A., 3rd et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J. Clin. Invest 115, 3205-3216 (2005).
17. Smith, K. G., Light, A., Nossal, G. J. & Tarlinton, D. M. The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary mmune response. EMBO J. 16, 2996-3006 (1997) (Pubitemid 27234939)
18. Blink, E. J. et al. early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J. Exp. Med. 201, 545-554 (2005). (Pubitemid 40289545)
19. William, J., Euler, C., Christensen, S. & Shlomchik, M. J. evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 297, 2066-2070 (2002).
20. Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903-1915 (2007). (Pubitemid 350074686)
21. Achatz-Straussberger, G. et al. Migration of antibody secreting cells towards CXCL12 depends on the isotype that forms the BCR. Eur. J. Immunol. 38, 3167-3177 (2008).
22. Holt, P G., Sedgwick, J. D., O'Leary, C., Krska, K. & Leivers, S. Long-lived Ige-and IgG-secreting cells in rodents manifesting persistent antibody responses. Cell. Immunol. 89, 281-289 (1984). (Pubitemid 15198330)
23. Voigt, C Characterization of short-and long-ived plasma cell populations in a murine model of systemic lupus erythematosus [German]. Thesis, Charité Univeritätsmedizin Berlin (2008).
24. Turner, C A. Jr., Mack, D. H. & Davis, M. M. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 77, 297-306 (1994). (Pubitemid 24138626)
25. Shapiro-Shelef, M., Lin, K. I., Savitsky, D., Liao, J. & Calame, K. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J. Exp. Med. 202, 1471-1476 (2005). (Pubitemid 41746593)
26. Shapiro-Shelef, M. & Calame, K. Regulation of plasma-cell development. Nat Rev. Immunol. 5, 230-242 (2005). (Pubitemid 40364824)
27. Kallies, A. et al. Initiation of plasma-cel differentiation is independent of the transcription factor Blimp-1. Immunity 26, 555-566 (2007). (Pubitemid 46766640)
28. Manz, R. A. et al. Humoral immunity and long-ived plasma cells. Curr. Opin. Immunol. 14, 517-521 (2002). (Pubitemid 34671256)
29. Benner, R., Hijmans, W. & Haaijman, J. J. The bone marrow: the major source of serum mmunoglobulins, but still a neglected site of antibody formation. Clin. Exp. Immunol. 46, 1-8 (1981). (Pubitemid 11005061)
30. Haaijman, J. J., Schuit, H. R. & Hijmans, W. mmunoglobulin-containing cells in different lymphoid organs of the CBA mouse during its ife-span. Immunology 32, 427-434 (1977). (Pubitemid 8061891)
31. Brieva, J. A., Roldán, E., De la Sen, M. L. & Rodriguez, C Human in vivo-induced spontaneous IgG-secreting cells from tonsil, blood and bone marrow exhibit different phenotype and functional level of maturation. Immunology 72, 580-583 (1991).
32. Cassese, G. et al. Inflamed kidneys of NZB/w mice are a major site for the homeostasis of plasma cells. Eur. J. Immunol. 31, 2726-2732 (2001). (Pubitemid 32898740)
33. Van Laar, J. M. et al. Sustained secretion of mmunoglobulin by long-lived human tonsi plasma cells. Am. J. Pathol. 171, 917-927 (2007). (Pubitemid 47440990)
34. Hiepe, F. & Radbruch, A. Is long-term humoral mmunity in the mucosa provided by long-lived plasma cells? A question still open. Eur. J. Immunol. 36, 1068-1069 (2006).
35. Cassese, G. et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J. Immunol. 171, 1684-1690 (2003). (Pubitemid 36966450)
36. Tokoyoda, K., Egawa, T., Sugiyama, T., Choi, B. I. & Nagasawa, T Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20, 707-718 (2004). (Pubitemid 38757441)
37. Tokoyoda, K., Hauser, A. e., Nakayama, T & Radbruch, A. Organization of immunological memory by bone marrow stroma. Nat Rev. Immunol. 10, 193-200 (2010)
38. Chu, v. T., Fröhich, A., Steinhauser, G., Scheel. T., Roch, T., Fillatreau, S., Lee, J. J., Löhning, M. & Berek, C eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol. (in press).
39. Winter, O. et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood 116, 1867-1875 (2010).
40. Geffroy-Luseau, A., Jégo, G., Bataille, R., Campion, L & Pellat-Deceunynck, C Osteoclasts support the survival of human plasma cells in vitro. Int Immunol. 20, 775-782 (2008). (Pubitemid 351791521)
41. O'Connor, B. P et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91-98 (2004).
42. Avery, D. T et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest 112, 286-297 (2003). (Pubitemid 38056364)
43. Benson, M. J. et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180, 3655-3659 (2008).
44. Gross, J. A. et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cel autoimmune disease. Nature 404, 995-999 (2000). (Pubitemid 30243593)
45. Belnoue, E. et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111, 2755-2764 (2008).
46. Underhill, G. H., Minges Wols, H. A., Fornek, J. L., Witte, P L & Kansas, G. S. IgG plasma cells display a unique spectrum of leukocyte adhesion and homing molecules. Blood 99, 2905-2912 (2002). (Pubitemid 34525380)
47. Chevrier, S. et al. CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche. Proc. Natl Acad. Sci. USA 106, 3895-3900 (2009).
48. Xiang, Z. et al. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol. 8, 419-429 (2007). (Pubitemid 46745417)
49. Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 14, 748-755 (2008). (Pubitemid 351951516)
50. Mumtaz, I. M. effects of immunosuppressive drugs and CD4+ T cell depletion on plasma cel survival in lupus prone (NZB/w) mice. Thesis, Charité Universitätsmedizin Berlin (2009).
51. Jacobi, A. M. et al. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 69, 305-308 (2010).
52. Ahuja, A., Anderson, S. M., Khalil, A. & Shlomchik, M. J. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl Acad. Sci. USA 105, 4802-1807 (2008).
53. DiLillo, D. J. et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol. 180, 361-371 (2008).
54. Cambridge, G. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48, 2146-2154 (2003). (Pubitemid 36959194)
55. Ferraro, A. J., Drayson, M. T., Savage, C O. & MacLennan, I. C Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur. J. Immunol. 38, 292-298 (2008).
56. Ahmed, A. R., Spigelman, Z., Cavacini, L. A. & Posner, M. R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 355, 1772-1779 (2006). (Pubitemid 44631360)
57. Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011-1016 (2008). (Pubitemid 351956665)
58. Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793-2806 (2006). (Pubitemid 44497758)
59. Edwards, J. C et al. efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004). (Pubitemid 38758544)
60. Ioannou, Y et al. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann. Rheum. Dis. 67, 425-426 (2008). (Pubitemid 351281283)
61. Lu, T. Y et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic upus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 61, 482-487 (2009).
62. Smith, K. G., Jones, R. B., Burns, S. M. & Jayne, D. R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 54, 2970-2982 (2006). (Pubitemid 44497778)
63. Tew, G. w. et al. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following Rituximab treatment in systemic lupus erythematosus. Lupus 19, 146-157 (2010).
64. Ng, K. P et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis. 66, 1259-1262 (2007). (Pubitemid 47309748)
65. Vallin, H., Perers, A., Alm, G. v. & Rönnblom, L. Anti-double-stranded DNA antibodies and mmunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic upus erythematosus. J. Immunol. 163, 6306-6313 (1999).
66. Eloranta, M. L. et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 56, 3112-3124 (2007).
67. Baccala, R., Hoebe, K., Kono, D. H., Beutler, B. & Theofilopoulos, A. N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med. 13, 543-551 (2007). (Pubitemid 46828489)
68. Hall, J. C & Rosen, A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev. Rheumatol. 6, 40-49 (2010).
69. Banchereau, J., Pascual, v. & Palucka, A. K. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20, 539-550 (2004). (Pubitemid 38638124)
70. Clavel, C et al. Induction of macrophage secretion of tumor necrosis factor α through Fcgγ receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 58, 678-688 (2008). (Pubitemid 351364865)
71. Shlomchik, M. J. Activating systemic autoimmunity: B's, T's, and tolls. Curr. Opin. Immunol. 21, 626-633 (2009).
72. Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526-1533 (2003). (Pubitemid 37255038)
73. Nielen, M. M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380-386 (2004). (Pubitemid 38198821)
74. Rantapää-Dahlqvist, S. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48, 2741-2749 (2003). (Pubitemid 37280601)
75. Teng, Y K., Levarht, e. w., Toes, R. e., Huizinga, T. w. & van Laar, J. M. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cel infiltration and enhanced B cell repopulation. Ann. Rheum. Dis. 68, 1011-1016 (2009).
76. Sekine, H., Watanabe, H. & Gilkeson, G. S. enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice. J. Immunol. 172, 3913-3921 (2004). (Pubitemid 38337979)
77. Salomonsson, S. et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum. 48, 3187-3201 (2003). (Pubitemid 37409331)
78. Tengner, P., Halse, A. K., Haga, H. J., Jonsson, R. & wahren-Herlenius, M. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren's syndrome. Arthritis Rheum. 41, 2238-2248 (1998). (Pubitemid 29009383)
79. Odendahl, M. et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105, 1614-1621 (2005). (Pubitemid 40223682)
80. Höfer, T. et al. Adaptation of humoral memory. Immunol. Rev. 211, 295-302 (2006). (Pubitemid 43882980)
81. Bernasconi, N. L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202 (2002). (Pubitemid 35471246)
82. Odendahl, M. et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165, 5970-5979 (2000).
83. Sykes, M. & Nikolic, B. Treatment of severe autoimmune disease by stem-cel transplantation. Nature 435, 620-627 (2005). (Pubitemid 40825502)
84. Tyndall, A. & Gratwohl, A. Adult stem cel transplantation in autoimmune disease. Curr. Opin. Hematol. 16, 285-291 (2009).
85. Nikolov, N. P & Pavletic, S. Z. Technology Insight: hematopoietic stem cel transplantation for systemic rheumatic disease. Nat. Clin. Pract. Rheumatol. 4, 184-191 (2008).
86. Zand, M. S. et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79, 1507-1515 (2005). (Pubitemid 40847581)
87. Zand, M. S. et al. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood 107, 2895-2903 (2006).
88. Alexander, T. et al. Depletion of autoreactive mmunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLe induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113, 214-223 (2009).
89. Meister, S. et al. extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67, 1783-1792 (2007). (Pubitemid 46383406)
90. Everly, M. J. et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am. J. Transplant. 9, 1063-1071 (2009).
91. Everly, M. J. et al. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc 41, 105-107 (2009).
92. Trivedi, H. L. et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 87, 1555-1561 (2009).
93. Ngo, H. T. et al. SDF-1/CXCR4 and vLA-4 interaction regulates homing in waldenstrom macroglobulinemia. Blood 112, 150-158 (2008).
94. Azab, A. K. et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113, 4341-4351 (2009).
95. Ramanujam, M. et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLe. J. Clin. Invest 116, 724-734 (2006). (Pubitemid 43326881)
96. Dall'era, M. et al. Reduced B lymphocyte and mmunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 56, 4142-4150 (2007). (Pubitemid 350262342)
97. Jacobi, A. M. et al. effect of long-term belimumab treatment on b cells in systemic upus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 62, 201-210 (2009).
98. Moser, K., Tokoyoda, K., Radbruch, A., MacLennan, I. & Manz, R. A. Stromal niches, plasma cell differentiation and survival. Curr. Opin. Immunol. 18, 265-270 (2006).
99. Yao, K. et al. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS ONE 3, e2028 (2008).
100. Yoshida, T. et al. Memory B and memory plasma cells. Immunol. Rev. 237, 117-139 (2010).
101. Ikeda, H. et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 15, 4028-4037 (2009).
102. Polson, A. G. & Sliwkowski, M. X. Toward an effective targeted chemotherapy for multiple myeloma. Clin. Cancer Res. 15, 3906-3907 (2009).
103. Post, J., Vooijs, W. C., Bast, B. J. & De Gast, G. C efficacy of an anti-CD138 mmunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells. Int J. Cancer 83, 571-576 (1999). (Pubitemid 29489875)
104. Martins, G. & Calame, K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu. Rev. Immunol. 26, 133-169 (2008). (Pubitemid 351600373)